Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

December 13, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten

As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and …
News
novartis_window

Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration

December 13, 2019 Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma

Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …
News

FDA U-turns to approve Sarepta’s Vyondys 53 in Duchenne muscular dystrophy

December 13, 2019 Medical Communications, Sales and Marketing FDA, Vyondys 53, pharma, sarepta

The FDA has surprised industry pundits by choosing to approve Sarepta’s Vyondys 53 under an accelerated pathway for the treatment …
News

Shionogi’s Mulpleo recommended for NHS use across England, Wales and Scotland for chronic liver disease

December 12, 2019 Sales and Marketing England, Mulpleo, NICE, Scotland, Scottish Medicines Consortium, Shionogi, Wales

Both the regulators governing NHS use of medicines in England, Wales and Scotland – the National Institute for Health and …
News
china-1081714_1920

China approves AstraZeneca’s Imfinzi for advanced non-small cell lung cancer

December 12, 2019 Sales and Marketing AstraZeneca, Imfinzi, pharma

AstraZeneca’s Imfinzi (durvalumab) is set to be made available in China after the country’s National Medical Products Administration (NMPA) decided …
News
shutterstock_512649

New NAFTA terms put hold on Canadian drug prices

December 11, 2019 Research and Development, Sales and Marketing Canada, NAFTA, US, pharma

NAFTA members have agreed to remove a provision that would have increased protections on biologics drugs. This means Canada, despite …
News
fdaoutsideweb

Correvio’s atrial fibrillation drug voted down by FDA committee over safety concerns

December 11, 2019 Research and Development, Sales and Marketing Correvio Pharma, FDA, atrial fibrillation, pharma

It has emerged that Correvio Pharma’s anti-arrhythmic therapy Brinavess was shot down by the FDA’s Cardiovascular and Renal Drugs Advisory …
News
msd

MSD set to acquire ArQule in deal worth up to $2.7 billion

December 10, 2019 Manufacturing and Production, Medical Communications, Sales and Marketing MSD, acquisition, arqule, pharma

MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, …
News

Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels

December 9, 2019 Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology

Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients …
News
ebolllaaaa

Johnson & Johnson to support Rwanda’s preparations against Ebola outbreak

December 9, 2019 Sales and Marketing Ebola, Ebola Guniea, Ebola virus

Johnson & Johnson will provide up to 200,000 Ebola vaccines to the Republic of Rwanda, through its pharmaceutical subsidiary Janssen. …
News
abbvie_0

Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia

December 9, 2019 Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …
News

AstraZeneca’s trial of leukaemia drug Calquence yields positive results

December 9, 2019 Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3

AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …
News

Sanofi acquires biotech firm Synthorx for $2.5 billion

December 9, 2019 Sales and Marketing Genetic Alphabet, Sanofi, acute lymphoblastic leukaemia, leukaemia

Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion). Paul Hudson, …
News
shutterstock_138095450

Transactions in the pharma sector: Through the EU merger review looking-glass

December 9, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, feature, mergers & acquisitions, pharma

With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …
Feature
jj

J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma

December 9, 2019 Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026